What were the findings of the ADVANCE Trial?
The ADVANCE Trial determined that after 4.3 years of follow-up, subjects assigned to the combination of perindopril and indapamide had a mean reduction in blood pressure of 5.6/2.2 mmHg and a 9% reduction in the risk of a composite of major macrovascular and microvascular events (HR, 0.91; 95% CI, 0.83 1.00; P=0.04), but there was no reduction in the incidence of major macrovascular events, including stroke.